The quarterly results for Axsome Therapeutics, Inc. (NASDAQ:AXSM) were released last week, making it a good time to revisit its performance. Revenue hit US$121m in line with forecasts, although the company reported a statutory loss per share of US$1.22 that was somewhat smaller than the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

We check all companies for important risks. See what we found for Axsome Therapeutics in our free report.NasdaqGM:AXSM Earnings and Revenue Growth May 8th 2025

Taking into account the latest results, the most recent consensus for Axsome Therapeutics from 18 analysts is for revenues of US$614.7m in 2025. If met, it would imply a substantial 42% increase on its revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 39% to US$3.44. Before this earnings announcement, the analysts had been modelling revenues of US$617.2m and losses of US$3.28 per share in 2025. Overall it looks as though the analysts were a bit mixed on the latest consensus updates. Although revenue forecasts held steady, the consensus also made a moderate increase in its losses per share forecasts.

View our latest analysis for Axsome Therapeutics

The consensus price target held steady at US$176, seemingly implying that the higher forecast losses are not expected to have a long term impact on the company's valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Axsome Therapeutics at US$210 per share, while the most bearish prices it at US$143. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 60% growth on an annualised basis. That is in line with its 72% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 8.3% annually. So it's pretty clear that Axsome Therapeutics is forecast to grow substantially faster than its industry.

Story Continues

The Bottom Line

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Axsome Therapeutics. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at US$176, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Axsome Therapeutics analysts - going out to 2027, and you can see them free on our platform here.

We also provide an overview of the Axsome Therapeutics Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock,  here.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments